Between January 2020 and March 2023, over 170 new oncology treatments were approved by the FDA. New approvals for the first quarter of 2023 include treatments for non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, and leukaemia.
Last year, researchers made significant progress in the development of new psoriasis treatments, with the FDA approving four new treatments.
Recent studies have shown that VNS therapy and selective VNS (sVNS) therapy could have significant potential in help treating various neurological disorders including Alzheimer’s disease, Parkinson’s disease, and stroke, among others.
